provide update Thank an pleased be on clinical today you, I'm Longeveron's to Wa'el. here to progress.
announced our our with from HLHS. follow-up on HLHS update new week, data ELPIS-X Earlier for an with begin will we trial patients of Lomecel-B long-term program. this I First,
with historical XX% in trial, observed participated survival the Lomecel-B The XX for years the data for patients survival age, that ELPIS-X These and in data this to up heart five potential, patients years the benefits transplant survived remained of severe for of trials. to showed, disease. reinforce free who five XXX% clinical at compared
rare a underdeveloped with impairing heart is year is HLHS absent to reconstructive congenital current or approximately have been the in all Infants of and left As States. that comprised pump a care born babies The affects defect the ability of HLHS burdensome, per blood ventricle, heart and United X,XXX left age extraordinarily operations is always before treated, the condition three five. of reminder, standard this fatal.
can including heart interventions, even surviving HLHS is and long-term address mentality, with HLHS improve Further, to the to XX% development between that burden patients. with risk performance surgical delayed those only your are We children an hope and somewhere elevated with of XX% short-term play failure Lomecel-B out of cardiac in complications, adolescents. organ
was Procedure. Phase Today, in injected Lomecel ELPIS-X concurrent X.X patients years for all least at X during known X patients as which, monitored Stage also after have XX XX with the surgery, trial treatment. participated Glenn a been
show new reached data of by to mortality patients HLHS. those highly children These age. results have new XXX% enthusiasm have treatment, are for including patients, Glenn two showing that of years age treatment years data and who Procedure with undergo our five survived These historical ELPIS-X from the typically a reinforce HLHS Lomecel-B for trial as that can encouraging five have that than care compared transform clinical of XX% with potential more that after
standard HLHS. Furthermore, current comprise about the HLHS Surgery, after three the care years of third Stage the of surgery, most that sequence for of Stage the of undergo patients X last surgeries
ELPIS-X Institute from undergo HLHS has collected of and months after XX% this Blood XX Heart, third have require more either of shown transplant thus, data To-date, already trial surgery patients than Stage third that of period X and by from surgery. Historical die or Lung, undergone not illness do the eligible five the a The surgery. National the patients heart five
data excited totality to forward and by on progress. the this follow-up the ELPIS look building from of this I are We trial
updates II to trial. current continue cohort additional patient provide ELPIS ELPIS our I advancing We we monitor will as Phase IIa the while
HLHS reconstructive in As are trial, trial, clinical evaluate of Phase who with efficacy a reminder, Stage injection II intended ELPIS infants to X and this the a intramyocardial IIa trial is the undergoing safety of Lomecel-B surgery.
cardiac RVEF, of months treatment. fraction, measure right ELPIS remains XX post endpoint II ventricular function, in primary The Enrollment trial. ongoing at the is a key ejection
additional expect activated We site. fully clinical have clinical one seven sites add to and
to our Now, to for of Alzheimer's completed Phase enrollment Lomecel-B treatment of like we move in I'd In our of program. XXXX, November the Alzheimer's IIa disease trial on disease.
trial multiple patients Lomecel-B the mild a of a CLEAR X-arm As parallel the Phase MIND trial to the safety trial disease. Alzheimer's reminder, design, is called IIa dose designed placebo and clinical different XX-patient, evaluate to Lomecel-B two of in of with single levels infusions compared of randomized
the primary of occurrence of measured XX days the severe events serious safety, Our Lomecel-B. administration is as adverse endpoint within first after by --
magnetic biomarkers as MRI, endothelial/vascular function. and Secondary systems to relevant and or exploratory well resonance endpoints as include brain inflammation of by cognitive measures imaging, volumetry
Based progression may on clinical reducing data, a Alzheimer's even we or the brain growing clinical believe body disease-related the Lomecel-B inflammation. slow by disease reverse of of preclinical and prevent,
Neuronal pathogenesis cell have the death like Alzheimer’s of barrier of neurogenesis, by models shown improving contributor with effect, caused promoting function been the an neuron Lomecel-B blood-brain to in disease. substantial of the and endothelial anti-inflammatory In potentially early brain. disease, the to preclinical and is a Alzheimer's neuroinflammation significant formation MSCs cross process
with disease. demonstrated study, completed of In a patients Lomecel-B Ib safety Phase to Alzheimer's mild preliminary we moderate a previously
a results and Lomecel-B Phase we disease. IIa as treatment on further demonstrate for build trial, the potential the Alzheimer's to With those hope of
to of from trial share topline results expect the MIND CLEAR at We XXXX. the end
multiple an on aging-related decline It age-associated failure infections, is to the loss, systems outcomes falls, characterized for risk weight impairment, hospitalization across cope such even individuals updates clinical to cover frailty with as mobility stressors. to and by is fatigue, puts like Aging-related low and frailty activity now our weakness, program. function and reserve and death. sorry, leading -- physiological poor inability I'd and slowness higher at Finally, fractures,
endothelial At physical been and early patients, elderly the on stage immune may on trials, have function to effect. inflammation vascular measure their and using evaluating and Longeveron, the function biomarkers system have function. we've of particularly exploratory we Lomecel-B effect of been frail health In and
aging-related is development with clinical world. in focused the one Japan, of currently in populations on a the country Our oldest frailty strategy
XX XX.X be demographic population frailty As The to XX.X% is comprised older, overall of of prevalence the the representing million amongst Japan's X.X%. individuals aging-related estimated aged or XXXX, of of country.
quarter, to is randomized Japan. The split X-arm in Lomecel-B a trial placebo single the aging-related evenly well clinical frailty with evaluating of the we our patients Phase infusions. dosing patient X design announce X:X:X This Phase as levels two X of as in in were of parallel pleased trial, first Lomecel-B different
key ASRM, the of dosing The first Japan’s expected with is potential represents to of or the of and tremendous patient enroll this trial trial this XX of overarching cell an Medicine, support the the for step The therapeutic safety in potential, Regenerative providing towards which Act primary objective limited evaluate under patients is recognizes on approval Safety therapies. the goal. of to a an the eventual goal study
first results call the turn discuss to like James? quarter of Clavijo, now XXXX. CFO financial to I'd the to our Longeveron’s that, With over James for
